CAPTC is pleased to announce two new job aids, focused on mpox recognition, diagnosis, testing, treatment, and vaccination.
The shorter job aid is called “Mpox Clinical Recognition and Testing Quicksheet: Mpox Presentations vs. Common Exanthems.” It is intended as a print resource, to help facilitate clinical recognition of mpox in health care settings. The longer job aid, “Mpox Clinical Recognition and Testing Overview,” is intended as an electronic resource. It has links to a number of helpful mpox-related resources.
The goal of this training is to prepare staff of local health departments to perform effective disease intervention (DI) interviews for mpox. This training aims to build on disease intervention skills by applying knowledge of the complexities and nuances specifically related to mpox DI interviews.
Learning Objectives By the end of these trainings, you should be able to:
Communicate accurate information about mpox symptoms, transmission, prevention, treatment, and services.
Gain awareness of the lived experiences of gay, bi, other men who have sex with men (MSM), including transgender men, and other trans people as it relates to mpox.
Understand a sex-positive, person-centered approach to taking a sexual history for mpox.
Use motivational interviewing and health coaching tools to support clients in seeking vaccination, screening, or treatment for mpox.
Examine personal and structural biases to reduce stigma during mpox interviews.
URL Redirect: STOMP: Study of Tecovirimat for Mpox
Guides for patients and providers in English, Spanish, and Chinese. STOMP (www.stomptpoxx.org) is a clinical trial of oral tecovirimat (TPOXX) safety and efficacy. It is the preferred strategy for clinicians and local health jurisdictions to access oral TPOXX.
STI Clinical Update Webinar: California Mpox Update for Healthcare Providers – October 2023
Thursday, October 26, 2023 12:00 PM – 1:30 PM (PDT)
The California Department of Public Health (CDPH) continues to see statewide Mpox activity, including a large cluster in Los Angeles County. This webinar, presented by the California Prevention Training Center (CAPTC), features CDPH’s Mpox Clinical and Epidemiology teams, who will provide a clinical update and epidemiological overview of Mpox, and discuss new research findings relevant to primary care and other healthcare providers, including data on transmission, vaccine equity, and vaccine effectiveness. A question-and-answer session will follow.
Presented by:
Kayla Saadeh, MPH Mpox Epidemiology Unit Lead California Department of Public Health
Jessica Watson, MD, MPH Mpox Public Health Medical Officer and Acting Clinical Lead California Department of Public Health
Learning Objectives
Identify the clinical and epidemiological factors leading to Mpox infection, transmission, and severity as well as treatment options.
Apply the latest information and research on Mpox, including transmission characteristics, vaccine equity, and vaccine effectiveness, to your clinical practice to ensure patients are appropriately vaccinated, diagnosed, tested, and treated for Mpox.
Please note: CME not available for viewing the webinar recording.
STI Clinical Program Update: Mpox letter and Bicillin shortage
STI Clinical Program Updates: Mpox letter and Bicillin shortage
The California Department of Public Health (CDPH) STD Control Branch has released two new important communications on: (1) Preventing a Resurgence of Mpox Cases in California and (2) Addressing an ongoing Bicillin® L-A shortage.
CDPH is aware that – while the rate of California (CA) mpox cases has declined precipitously since its peak in August 2022 – mpox transmission has continued in CA, and other states have recently reported a resurgence of mpox cases. Accordingly, CDPH has released a new Dear Colleague Letter intended as a call to action to Californian health care providers to remain vigilant in mpox prevention, recognition, and testing. This is especially important during the upcoming 2023 spring and summer season as people gather for festivals and events, including LGBTQ Pride Month in June. Information on how to diagnose, test for, and vaccinate against mpox is included.
(2) Health Advisory: Bicillin® L-A (Benzathine Penicillin G) Shortage
The Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) have announced a shortage of long-acting penicillin G benzathine injectable suspension products (Bicillin® L-A), with an estimated recovery timeframe not until Q4 of 2023. This is of considerable concern in CA, as the state continues to see significant increases in syphilis — including syphilis in pregnant persons and congenital syphilis in infants. CDPH has thus issued a Health Advisory addressing the Bicillin® L-A shortage, providing a framework for prioritization of limited Bicillin® L-A supplies when necessary, and recommending doxycycline as an alternative to Bicillin® L-A in appropriate clinical scenarios.
Sincerely,
California Prevention Training Center
Preventing Occupational Mpox Transmission in Outpatient Clinics
Preventing Occupational Mpox Transmission in Outpatient Clinics
This resource includes practical tips for preventing mpox transmission in an outpatient setting, as implemented by many sexual health clinics during the current mpox outbreak. When space and resources are scarce or limited, implementing these real-world strategies allows clinics to care for patients with mpox as safely and effectively as possible.
Excellent FAQs and resources from Building Healthy Online Communities on the latest in mpox (formerly known as monkeypox) prevention, transmission, symptoms, and treatment. Updated regularly.
CDC resource center for the latest updates on mpox (formerly known as monkeypox). Includes information on spread, vaccines, signs and symptoms, news, related conditions, pediatric considerations, and more.
We use cookies to ensure that we give you the best experience on our website, but we also recognize the right to privacy. Please accept or disable cookies for this website.AcceptDisable
